Compound class:
Synthetic organic
Comment: MI-3 inhibits the interaction between MLL oncoproteins (re-arranged lysine (K)-specific methyltransferases) and the tumour suppressor protein menin (MEN1, O00255) [1]. MI-3 represents a novel molecular mechanism with potential application in the treatment of aggressive leukemias with MLL rearrangements.
|
|
References |
1. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM, Hartley T et al.. (2012)
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol, 8 (3): 277-84. [PMID:22286128] |
2. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA et al.. (2004)
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell, 13 (4): 587-97. [PMID:14992727] |
3. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML. (2004)
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol, 24 (13): 5639-49. [PMID:15199122] |